Genome & Company
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The c… Read more
Genome & Company (314130) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.065x
Based on the latest financial reports, Genome & Company (314130) has a cash flow conversion efficiency ratio of -0.065x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-6.18 Billion) by net assets (₩95.37 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genome & Company - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Genome & Company's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genome & Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genome & Company ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Lianming Machinery Co Ltd
SHG:603006
|
0.006x |
|
Guangdong Jushen Logistics Co Ltd
SHE:001202
|
-0.042x |
|
HUA YU LIEN Development Co Ltd
TW:1436
|
-0.040x |
|
Sariguna Primatirta PT
JK:CLEO
|
0.043x |
|
Fujian Yuanxiang New Materials Co. Ltd. A
SHE:301300
|
N/A |
|
Chison Medical Technologies Co Ltd
SHG:688358
|
0.012x |
|
Eagle Financial Services Inc Common Stock
OTCQX:EFSI
|
0.044x |
|
Sedlmayr Grund und Immobilien AG
F:SPB
|
N/A |
Annual Cash Flow Conversion Efficiency for Genome & Company (2021–2024)
The table below shows the annual cash flow conversion efficiency of Genome & Company from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩48.31 Billion | ₩-7.61 Billion | -0.158x | +68.28% |
| 2023-12-31 | ₩62.43 Billion | ₩-31.00 Billion | -0.497x | -34.19% |
| 2022-12-31 | ₩97.30 Billion | ₩-36.00 Billion | -0.370x | -60.41% |
| 2021-12-31 | ₩113.40 Billion | ₩-26.16 Billion | -0.231x | -- |